REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

26 10 2023 16:00:07 提供 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

25 10 2023 16:05:00 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

22 10 2023 14:59:00 提供 Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

21 10 2023 08:48:15 提供 Nasdaq GlobeNewswire

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

20 10 2023 17:00:37 提供 Nasdaq GlobeNewswire

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

18 10 2023 09:30:00 提供 Nasdaq GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

18 10 2023 09:00:00 提供 Nasdaq GlobeNewswire

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

15 10 2023 18:05:23 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 10 2023 09:48:32 提供 NetDania Notify

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

05 10 2023 09:43:00 提供 Nasdaq GlobeNewswire

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

29 9 2023 08:30:12 提供 Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

28 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

26 9 2023 01:29:00 提供 Nasdaq GlobeNewswire

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

25 9 2023 08:34:45 提供 Nasdaq GlobeNewswire

Regeneron Provides Update on Planned Chief Financial Officer Transition

08 9 2023 16:46:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Updates to Board of Directors

08 9 2023 16:45:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

23 8 2023 16:05:00 提供 Nasdaq GlobeNewswire

Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention

22 8 2023 14:15:41 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

22 8 2023 10:15:09 提供 NetDania Notify